Aldosterone is associated with left ventricular hypertrophy in hemodialysis patients

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Patients with chronic kidney disease (CKD) often exhibit greater left ventricular hypertrophy (LVH) than expected for their hypertension levels.
• The relationship between aldosterone and cardiac remodeling in CKD patients requires further investigation.
• Existing data suggests a potential role for aldosterone in the altered fluid balance (extracellular water/total body water quotient) seen in CKD.

Purpose of the Study:

• To investigate the association between serum aldosterone levels and left ventricular mass index (LVMI) in patients with CKD undergoing hemodialysis.
• To explore the role of aldosterone in cardiac remodeling within this specific patient population.

Main Methods:

• A cohort of 27 CKD patients on hemodialysis were assessed using clinical evaluations, laboratory tests, bioelectrical impedance, echocardiography, and ambulatory blood pressure monitoring.
• Patients were stratified into two groups based on serum aldosterone levels for comparative analysis.
• Multiple linear regression analysis was employed to adjust for confounding variables.

Main Results:

• Patients with higher serum aldosterone levels demonstrated a significantly higher left ventricular mass index.
• Aldosterone levels were independently associated with left ventricular mass index after adjusting for confounding factors.
• While some baseline characteristics differed (e.g., systolic blood pressure, BMI), key parameters like extracellular water/total body water quotient and use of certain medications were similar between groups.

Conclusions:

• The findings support a pathogenic role for aldosterone in the development of left ventricular hypertrophy in patients with chronic kidney disease on hemodialysis.
• Elevated aldosterone may contribute to cardiac remodeling in this vulnerable patient group.